Menu Search
Equities

Adocia SA

ADOC:PAR

Adocia SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)9.70
  • Today's Change0.150 / 1.57%
  • Shares traded20.49k
  • 1 Year change+171.71%
  • Beta0.5553
Data delayed at least 15 minutes, as of May 20 2024 09:52 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Adocia SA's revenues fell -81.22% from 11.45m to 2.15m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 6.90m to a larger loss of 21.16m.
Gross margin--
Net profit margin-358.85%
Operating margin-263.83%
Return on assets-65.43%
Return on equity--
Return on investment-341.43%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Adocia SA fell by 4.46m. Cash Flow from Financing totalled 629.00k or 29.26% of revenues. In addition the company used 4.95m for operations while cash used for investing totalled 138.00k.
Cash flow per share-2.30
Price/Cash flow per share--
Book value per share-1.90
Tangible book value per share-1.90
More ▼

Balance sheet in EURView more

Adocia SA has a Debt to Total Capital ratio of 281.45%.
Current ratio0.5967
Quick ratio0.5924
Total debt/total equity--
Total debt/total capital2.81
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.